Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 2
2017 2
2018 4
2019 12
2020 5
2021 2
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib.
Jonas K, Prinz F, Ferracin M, Krajina K, Pasculli B, Deutsch A, Madl T, Rinner B, Slaby O, Klec C, Pichler M. Jonas K, et al. Among authors: klec c. Breast Cancer Res. 2023 Oct 6;25(1):119. doi: 10.1186/s13058-023-01716-2. Breast Cancer Res. 2023. PMID: 37803350 Free PMC article.
ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform.
Klec C, Knutsen E, Schwarzenbacher D, Jonas K, Pasculli B, Heitzer E, Rinner B, Krajina K, Prinz F, Gottschalk B, Ulz P, Deutsch A, Prokesch A, Jahn SW, Lellahi SM, Perander M, Barbano R, Graier WF, Parrella P, Calin GA, Pichler M. Klec C, et al. Cell Mol Life Sci. 2022 Jul 1;79(7):391. doi: 10.1007/s00018-022-04402-2. Cell Mol Life Sci. 2022. PMID: 35776213 Free PMC article.
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Barth DA, Stanzer S, Spiegelberg JA, Bauernhofer T, Absenger G, Szkandera J, Gerger A, Smolle MA, Hutterer GC, Ahyai SA, Madl T, Posch F, Riedl JM, Klec C, Jost PJ, Kargl J, Stradner MH, Pichler M. Barth DA, et al. Among authors: klec c. Front Immunol. 2022 Apr 1;13:840207. doi: 10.3389/fimmu.2022.840207. eCollection 2022. Front Immunol. 2022. PMID: 35432362 Free PMC article.
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Barth DA, Stanzer S, Spiegelberg J, Bauernhofer T, Absenger G, Posch F, Lipp R, Halm M, Szkandera J, Balic M, Gerger A, Smolle MA, Hutterer GC, Klec C, Jost PJ, Kargl J, Stradner M, Pichler M. Barth DA, et al. Among authors: klec c. Cancer Med. 2022 Aug;11(16):3074-3083. doi: 10.1002/cam4.4675. Epub 2022 Mar 16. Cancer Med. 2022. PMID: 35297215 Free PMC article.
Non-Coding RNAs and SARS-Related Coronaviruses.
Henzinger H, Barth DA, Klec C, Pichler M. Henzinger H, et al. Among authors: klec c. Viruses. 2020 Dec 1;12(12):1374. doi: 10.3390/v12121374. Viruses. 2020. PMID: 33271762 Free PMC article. Review.
34 results